Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A and B) Changes in the apnoea hypopnoea index (AHI) and 3% oxygen desaturation index (ODI) from baseline to treatment titration and 3 months of therapy:

Published byNaděžda Bártová Modified over 5 years ago

Similar presentations

Presentation on theme: "(A and B) Changes in the apnoea hypopnoea index (AHI) and 3% oxygen desaturation index (ODI) from baseline to treatment titration and 3 months of therapy:"— Presentation transcript:

1 (A and B) Changes in the apnoea hypopnoea index (AHI) and 3% oxygen desaturation index (ODI) from baseline to treatment titration and 3 months of therapy: full analysis set. (A and B) Changes in the apnoea hypopnoea index (AHI) and 3% oxygen desaturation index (ODI) from baseline to treatment titration and 3 months of therapy: full analysis set. Plotted line graphs indicate the mean±SE at each assessment. *One-way repeated measure analyses of variance (ANOVA) showed that both adaptive servoventilation (ASV) and oxygen therapy significantly decreased AHI (ASV: baseline 34.2±12.1, titration 10.0±10.2, follow-up 7.2±5.9/h, p<0.01; oxygen: baseline 36.9±9.9, titration 19.5±11.0, follow-up 19.4±8.4/h, p<0.01) and 3% ODI (ASV: baseline 28.2±15.6, titration 3.0±2.4, follow-up 3.9±4.1/h, p<0.01; oxygen: baseline 32.7±11.9, titration 3.3±5.6, follow-up 2.6±5.7/h, p<0.01) within the same group. †Two-way measured ANOVA showed that a significant difference was found in the changes in AHI (p=0.01) but not in 3% ODI (p=0.56) throughout the study between the two groups. Kimihiko Murase et al. Open Heart 2016;3:e000366 ©2016 by British Cardiovascular Society

Download ppt "(A and B) Changes in the apnoea hypopnoea index (AHI) and 3% oxygen desaturation index (ODI) from baseline to treatment titration and 3 months of therapy:"

Similar presentations

Oxygen Desaturation Index (ODI) Obstructive Apnoea (OA)

Oxygen Desaturation Index (ODI) Obstructive Apnoea (OA)
Comparison of prevalence of uncovered struts between ZES and EES groups. Comparison of prevalence of uncovered struts between ZES and EES groups. Scatter plot.

Comparison of prevalence of uncovered struts between ZES and EES groups. Comparison of prevalence of uncovered struts between ZES and EES groups. Scatter plot.
In vivo selectivity of compound 6b.

In vivo selectivity of compound 6b.
Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.

Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.
Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.

Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.
Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Change from baseline in the severity of night-time cough and the frequency of night-time sputum production at week 12 in ACCORD COPD I.17 Data are reported.

Change from baseline in the severity of night-time cough and the frequency of night-time sputum production at week 12 in ACCORD COPD I.17 Data are reported.
Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.

Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.
HOMA calculations where glucose is mmol/L and insulin is mU/L

HOMA calculations where glucose is mmol/L and insulin is mU/L
(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.
Comparison of CMR and echocardiography in aortic regurgitation.

Comparison of CMR and echocardiography in aortic regurgitation.
(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).
Change from baseline in the severity of morning cough and severity of difficulty bringing up phlegm in the morning over the study period in the active-comparator.

Change from baseline in the severity of morning cough and severity of difficulty bringing up phlegm in the morning over the study period in the active-comparator.
Correlation of change in H2 concentration (△H2) haemodynamics or laboratory parameters. Correlation of change in H2 concentration (△H2) haemodynamics or.

Correlation of change in H2 concentration (△H2) haemodynamics or laboratory parameters. Correlation of change in H2 concentration (△H2) haemodynamics or.
Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.
Toray microarray analysis of the four groups of patients (A) and in patients with calcium score >100 (B). Toray microarray analysis of the four groups.

Toray microarray analysis of the four groups of patients (A) and in patients with calcium score >100 (B). Toray microarray analysis of the four groups.
Changes in median exhaled CO levels from baseline to 12 weeks in quitters (n=183) and continuous smokers (n=94). Changes in median exhaled CO levels from.

Changes in median exhaled CO levels from baseline to 12 weeks in quitters (n=183) and continuous smokers (n=94). Changes in median exhaled CO levels from.
Baseline plasma levels of cathepsin D (A), cathepsin L (B) and cystatin B (C) are increased in individuals who developed coronary events (CEs) during follow-up.

Baseline plasma levels of cathepsin D (A), cathepsin L (B) and cystatin B (C) are increased in individuals who developed coronary events (CEs) during follow-up.

Similar presentations

Ads by Google